Table 1 CAR-T clinical pathway: activities not remunerated by fees

PHASE I: PATIENT ELIGIBILITY

Waiting list management

Patient eligibility evaluation and referral center communication

Evaluation protocols

PHASE II/III: PATIENT CONSENT + DRUG CHOICE

Consent form management

Drug choice

Communication to the relevant pharmaceutical companies

Contact with the apheresis transfusion service

First contact with the intensive care unit

PHASE IV: APHERESIS PLAN + DRUG BOOKING

Apheresis planning

Entering drug request in the company’s platform

Apheresis protocol

PHASE V: APHERESIS

Eligibility check

PHASE VI: BAG SENDING + LYMPHOCYTE ENGINEERING PROCEDURE + BAG RETURN

Bag shipping

Contact with the company for engineering project monitoring

Bag reception, preparation and planning

Transplant program checklist

Pharmacy, surgery and cryopreservation checklist

PHASE VII: ADMISSION PLANNING

Pre-hospitalization patient assessment

Pre-admission checklist

Infusion preparation and administrative activities (including compiling drug registry)

PHASE VIII: ADMISSION / RECEPTION OF THE BAG

First contact with the intensive care unit

Lymphodepleting chemotherapy check

Return of modified leukocytes

PHASE IX: HOSPITALIZATION / INFUSION + MONITORING

Protocols / SOPs

PHASE X: HOSPITAL / TOXICITY MANAGEMENT

Toxicity management protocols

Activation of beds in other units

PHASE XI: DISCHARGE

Preparation of the discharge documents

PHASE XII: FOLLOW UP

Protocols for managing toxicities

Compiling follow-up drug registry form